SCHEMBL6189092

SCHEMBL6189092

COc1cc(S[C@H](C[C@H](N)CO)c2ccccc2F)c(C#N)cn1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
CTSA P10619 1/20 0.32
CYP2D6 P10635 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
NOS2 P35228 1/20 0.31
ROCK2 O75116 1/20 0.30
ROCK1 Q13464 1/20 0.30
CYP11B1 P15538 1/20 0.30
CYP11B2 P19099 1/20 0.30
SLC6A3 Q01959 1/20 0.30
EGFR P00533 1/20 0.30
ERBB2 P04626 1/20 0.30
STK4 Q13043 1/20 0.30
TRPV4 Q9HBA0 1/20 0.30
P2RX3 P56373 1/20 0.30
P2RX2 Q9UBL9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6185529 0.86 CYP2D6 (0.40) CYP3A4AAK1CYP2D6SLC6A2SLC6A4
SCHEMBL231183 0.86 CYP2D6 (0.40) CYP3A4AAK1CYP2D6SLC6A2SLC6A4
SCHEMBL6746295 0.86 CYP2D6 (0.40) CYP3A4AAK1CYP2D6SLC6A2SLC6A4
SCHEMBL231181 0.86 CYP2D6 (0.40) CYP3A4AAK1CYP2D6SLC6A2SLC6A4
SCHEMBL6187189 0.86 CYP2D6 (0.40) CYP3A4AAK1CYP2D6SLC6A2SLC6A4
SCHEMBL231182 0.86 CYP2D6 (0.40) CYP3A4AAK1CYP2D6SLC6A2SLC6A4
SCHEMBL6750050 0.86 CYP2D6 (0.40) CYP3A4AAK1CYP2D6SLC6A2SLC6A4
SCHEMBL6750078 0.83 AAK1 (0.33) CYP3A4AAK1
SCHEMBL6746353 0.80 CYP2D6 (0.39) CYP2D6SLC6A2SLC6A4NOS2ROCK2
SCHEMBL6748041 0.77 CYP2D6 (0.39) CYP2D6SLC6A2SLC6A4NOS2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572655-A2 NOVEL ARYLHETEROALKYLAMINE DERIVATIVES AstraZeneca AB (SE) 2005-09-14 EP claimed
US-20040242871-A1 Novel arylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2004-12-02 US claimed
WO-2002090332-A2 NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES ASTRAZENECA AB (SE) 2002-11-14 WO claimed
US-20040242871-A1 Novel arylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242871-A1 Novel arylheteroalkylamine derivatives CYP1A1, NOS3, NOS1 CYP3A4 47/4885AAK1 702/4885CTSA 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.